Posted by Michael Wonder on 08 Sep 2022
Pharmac issues RFP for intravenous trastuzumab, a medicine used to treat breast cancer
8 September 2022 - PHARMAC is seeking commercial bids from pharmaceutical suppliers for the supply of intravenous trastuzumab, a ‘biologic’ medicine currently funded to treat New Zealanders with breast cancer.
“Biologics are among the most expensive medicines that PHARMAC funds, with expenditure on trastuzumab (branded as Herceptin) in the top 5 gross medicines costs for reimbursed medicines in 2021.”
